Literature DB >> 22350961

No evidence of XMRV infection in immunocompromised patients and HIV-positive individuals from Germany.

K Korn1, H Reil, A Ensser, A Knöll.   

Abstract

BACKGROUND: Xenotropic murine leukaemia virus-related virus (XMRV) has been detected in patients with prostate cancer and chronic fatigue syndrome (CFS). The detection of XMRV in healthy individuals has raised concern about a possible virus transmission by blood products. However, recent studies challenge the association between XMRV and human disease. This study investigated whether or not XMRV is present in patients with altered immune function and individuals at increased risk of blood-borne viral infections in Germany.
METHODS: We investigated 503 peripheral blood mononuclear cell (PBMC) samples from 240 patients with iatrogenic immune suppression (71 haematopoietic stem cell recipients, 132 solid organ transplant recipients, 37 others) and 311 PBMC samples from 302 patients with HIV-1 infection for the presence of proviral XMRV by real-time polymerase chain reaction (PCR).
RESULTS: All 814 PBMC samples from 542 patients tested negative for XMRV DNA and positive for an internal herpesvirus saimiri (HVS) control. Human genomic DNA was detected in all samples, and 90% of the samples contained >10,000 cell equivalents per XMRV PCR reaction.
CONCLUSIONS: Our failure to detect proviral XMRV provides evidence against the presence of XMRV in patients at increased risk of viral infections in Germany.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22350961     DOI: 10.1007/s15010-012-0249-2

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  25 in total

1.  A cautionary tale of virus and disease.

Authors:  Robin A Weiss
Journal:  BMC Biol       Date:  2010-09-27       Impact factor: 7.431

2.  No evidence of murine-like gammaretroviruses in CFS patients previously identified as XMRV-infected.

Authors:  Konstance Knox; Donald Carrigan; Graham Simmons; Fernando Teque; Yanchen Zhou; John Hackett; Xiaoxing Qiu; Ka-Cheung Luk; Gerald Schochetman; Allyn Knox; Andreas M Kogelnik; Jay A Levy
Journal:  Science       Date:  2011-05-31       Impact factor: 47.728

3.  Recombinant origin of the retrovirus XMRV.

Authors:  Tobias Paprotka; Krista A Delviks-Frankenberry; Oya Cingöz; Anthony Martinez; Hsing-Jien Kung; Clifford G Tepper; Wei-Shau Hu; Matthew J Fivash; John M Coffin; Vinay K Pathak
Journal:  Science       Date:  2011-05-31       Impact factor: 47.728

4.  Absence of evidence of xenotropic murine leukemia virus-related virus infection in persons with chronic fatigue syndrome and healthy controls in the United States.

Authors:  William M Switzer; Hongwei Jia; Oliver Hohn; HaoQiang Zheng; Shaohua Tang; Anupama Shankar; Norbert Bannert; Graham Simmons; R Michael Hendry; Virginia R Falkenberg; William C Reeves; Walid Heneine
Journal:  Retrovirology       Date:  2010-07-01       Impact factor: 4.602

5.  XMRV is present in malignant prostatic epithelium and is associated with prostate cancer, especially high-grade tumors.

Authors:  Robert Schlaberg; Daniel J Choe; Kristy R Brown; Harshwardhan M Thaker; Ila R Singh
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-08       Impact factor: 11.205

6.  No association of xenotropic murine leukemia virus-related virus with prostate cancer or chronic fatigue syndrome in Japan.

Authors:  Rika A Furuta; Takayuki Miyazawa; Takeki Sugiyama; Hirohiko Kuratsune; Yasuhiro Ikeda; Eiji Sato; Naoko Misawa; Yasuhito Nakatomi; Ryuta Sakuma; Kazuta Yasui; Kouzi Yamaguti; Fumiya Hirayama
Journal:  Retrovirology       Date:  2011-03-17       Impact factor: 4.602

7.  No evidence of XMRV in prostate cancer cohorts in the Midwestern United States.

Authors:  Toshie Sakuma; Stéphane Hué; Karen A Squillace; Jason M Tonne; Patrick R Blackburn; Seiga Ohmine; Tayaramma Thatava; Greg J Towers; Yasuhiro Ikeda
Journal:  Retrovirology       Date:  2011-03-29       Impact factor: 4.602

8.  No detection of XMRV in blood samples and tissue sections from prostate cancer patients in Northern Europe.

Authors:  Kristin Stieler; Sarah Schindler; Thorsten Schlomm; Oliver Hohn; Norbert Bannert; Ronald Simon; Sarah Minner; Michael Schindler; Nicole Fischer
Journal:  PLoS One       Date:  2011-10-12       Impact factor: 3.240

9.  Failure to detect the novel retrovirus XMRV in chronic fatigue syndrome.

Authors:  Otto Erlwein; Steve Kaye; Myra O McClure; Jonathan Weber; Gillian Wills; David Collier; Simon Wessely; Anthony Cleare
Journal:  PLoS One       Date:  2010-01-06       Impact factor: 3.240

10.  Lack of evidence for xenotropic murine leukemia virus-related virus(XMRV) in German prostate cancer patients.

Authors:  Oliver Hohn; Hans Krause; Pia Barbarotto; Lars Niederstadt; Nadine Beimforde; Joachim Denner; Kurt Miller; Reinhard Kurth; Norbert Bannert
Journal:  Retrovirology       Date:  2009-10-16       Impact factor: 4.602

View more
  4 in total

Review 1.  Recombinant origin, contamination, and de-discovery of XMRV.

Authors:  Krista Delviks-Frankenberry; Oya Cingöz; John M Coffin; Vinay K Pathak
Journal:  Curr Opin Virol       Date:  2012-07-19       Impact factor: 7.090

2.  Variant morphology and random chromosomal integration of BK polyomavirus in posttransplant urothelial carcinomas.

Authors:  Simone Bertz; Armin Ensser; Robert Stoehr; Markus Eckstein; Hendrik Apel; Doris Mayr; Maike Buettner-Herold; Nadine Therese Gaisa; Eva Compérat; Bernd Wullich; Arndt Hartmann; Antje Knöll
Journal:  Mod Pathol       Date:  2020-02-11       Impact factor: 7.842

3.  No biological evidence of XMRV infection in cervical smears from HIV/ HPV positive and negative Kenyan women.

Authors:  Xiaotong He; Thomas D J Walker; Innocent O Maranga; Anthony W Oliver; Lynne Hampson; Ian N Hampson
Journal:  PLoS One       Date:  2012-10-08       Impact factor: 3.240

4.  Characterization of a universal screening approach for congenital CMV infection based on a highly-sensitive, quantitative, multiplex real-time PCR assay.

Authors:  Angela Nagel; Emmanouela Dimitrakopoulou; Norbert Teig; Peter Kern; Thomas Lücke; Dariusz Michna; Klaus Korn; Philipp Steininger; Khalid Shahada; Katrin Neumann; Klaus Überla
Journal:  PLoS One       Date:  2020-01-09       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.